Family Communications After Genetic Testing (NCT07143487)
Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about 15% of these patients have a disease-causing (pathogenic) inherited (germline) variant in a cancer susceptibility gene. Most individuals carrying a pathogenic germline variant are unaware of their cancer risk and may not meet guidelines for genetic testing. Identifying pathogenic germline variants or hereditary cancer syndromes in cancer patients has important implications for their at-risk relatives who may not know that they are at high risk for cancer. The burden of communicating this risk to first-degree relatives often falls on the patients, who may lack sufficient knowledge to correctly share and explain their genetic test results. Receiving provider-mediated communication of genetic testing results may be more effective at communicating genetic risk to first-degree relatives than the usual practice of proband-mediated communication.
Who can join: Review the eligibility criteria below.
Location: Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
- Biospecimen Collection (PROCEDURE)
- Genetic Testing (OTHER)
- Communication Intervention (OTHER)
- Survey Administration (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (299 Sites)
Showing the first 25 of 299 sites.
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
- Alaska Women's Cancer Care — Anchorage, Alaska
- Katmai Oncology Group — Anchorage, Alaska
- Providence Alaska Medical Center — Anchorage, Alaska
- Fairbanks Memorial Hospital — Fairbanks, Alaska
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
- Mercy Cancer Center — Merced, California
- Providence Queen of The Valley — Napa, California
- Mercy Cancer Center - Rocklin — Rocklin, California
- Mercy Cancer Center - Sacramento — Sacramento, California
- Pacific Central Coast Health Center-San Luis Obispo — San Luis Obispo, California
- Mission Hope Medical Oncology - Santa Maria — Santa Maria, California
- Providence Medical Foundation - Santa Rosa — Santa Rosa, California
- Providence Santa Rosa Memorial Hospital — Santa Rosa, California
- Saint Helena Hospital — St. Helena, California
- Saint Joseph's Medical Center — Stockton, California
📞 Contact the Study Coordinator
Phone: (773) 702-9814
Email: rwills@bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colon Adenocarcinoma
- Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery — Birmingham, Alabama
- Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer — Millville, Delaware
- Young-Onset Colorectal Cancer — Conroe, Texas
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair — Anchorage, Alaska
- Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas — Orange, California
- Evaluating Novel Therapies in ctDNA Positive GI Cancers — Washington D.C., District of Columbia
Explore by condition: All Colon Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.